Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Amoxicillin-Clavulanate

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Drops Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
Apr 25, 2026, 10:05 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Apr 22, 2026, 10:02 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed Apr 25, 2026, 10:05 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 15, 2026

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Image coming soon
Amoxicillin-Clavulanate

Amoxicillin-Clavulanate

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Drops Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Amoxicillin-Clavulanate

Antibiotic combination used for susceptible bacterial infections (often skin, soft tissue, dental, urinary). Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied.

Generic name
Amoxicillin-Clavulanate
Brand names
Clavacillin®, Amoxicillin and Clavulanate Potassium Tablets, Amoxicillin and Clavulanate Potassium for Oral Suspension, Clavamox® Drops
Manufacturer
Multiple FDA labelers
Species
Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied, Dog, Not Breeding Animals
Dosage forms
Drops, Tablet, Suspension, Liquid
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Clavacillin® Amoxicillin and Clavulanate Potassium Tablets Amoxicillin and Clavulanate Potassium for Oral Suspension Clavamox® Drops Betacilin Clav Amoxicillin and Clavulanate Potassium UMBRELLIN Betacilin Clav Drops Amoxicillin and Clavulanate Potassium Drops Clavacillin
Dosage forms
Drops Tablet Suspension Liquid

Indications / Uses

Antibiotic combination used for susceptible bacterial infections (often skin, soft tissue, dental, urinary).

Administration / How To Give

Oral

Storage

Store at room temperature; follow label directions for liquid suspensions.

Warnings / Contraindications

Avoid in pets with known penicillin allergy. Use caution with severe kidney disease.

  • Avoid in pets with known penicillin allergy. Use caution with severe kidney disease.

Side Effects

GI upset (vomiting/diarrhea), decreased appetite. Rare: allergic reaction.

FAQ

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied, Dog, Not Breeding Animals, Cat, Not Breeding Animals

Yes. Roxee shows this as prescription-only.

Drops, Tablet, Suspension, Liquid

Store at room temperature; follow label directions for liquid suspensions.

Related Conditions

Abscesses (cat bite abscess) Periodontal Disease (Dental Disease) Periodontal Disease (Gingivitis/Periodontitis) Pyoderma (superficial/deep) Urinary tract infection (cystitis)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococc...

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Avoid in pets with known penicillin allergy
  • Use caution with severe kidney disease
  • Loss of appetite (1 reports)
  • Dullness (1 reports)
  • Drooling (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • Avoid in pets with known penicillin allergy
  • Use caution with severe kidney disease
  • Loss of appetite
  • Dullness
  • Drooling

Most reported reactions:

  • Loss of appetite (1 reports)
  • Dullness (1 reports)
  • Drooling (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Liquid, Suspension, Tablet
Identifiers:
ANADA: 200592 ANADA: 200604 ANADA: 200702 ANADA: 200709 NADA: 55101 NDC Package: 11695-6991-1 NDC Package: 11695-6992-1 NDC Package: 11695-6993-1 NDC Package: 11695-6994-1 NDC Package: 11695-7007-1 NDC Package: 13744-540-01 NDC Package: 13744-541-01 NDC Package: 13744-542-01 NDC Package: 13744-543-01 NDC Package: 17033-451-15 NDC Package: 46066-087-17 NDC Package: 46066-111-60 NDC Package: 46066-112-60 NDC Package: 46066-113-60 NDC Package: 46066-114-60
Source metadata:

Warnings / Contraindications

Avoid in pets with known penicillin allergy. Use caution with severe kidney disease.

  • High: Avoid in pets with known penicillin allergy. Use caution with severe kidney disease.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
31
Species represented
2
Grouped by Body System
Digestive (4) · Loss of appetite, Drooling, Diarrhea Neurologic (1) · Circling - neurological disorder Behavior (1) · Anxiety Other (26) · Dullness, Disoriented state, Disorientation
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Other 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Digestive 1 Cat 1
Other 1 Cat 1

Species coverage: Dog (28) Cat (4)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Storage & Handling

Store at room temperature; follow label directions for liquid suspensions.

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

18

FOI

5

Amoxicillin and Clavulanate Potassium for Oral Suspension

SPL · SPL

Open original
FDA Structured Product Label

Amoxicillin and Clavulanate Potassium for Oral Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
ANADA
200-709
Status
RX
Form
Suspension
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
When reconstituted each mL contains 50 mg of amoxicillin as the trihydrate and 12.5 mg of clavulanic acid as the potassium salt.

Dogs

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

Dosage

The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Cats

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.

Amoxicillin and Clavulanate Potassium Tablets

SPL · SPL

Open original
FDA Structured Product Label

Amoxicillin and Clavulanate Potassium Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Cronus Pharma Specialities India Private Ltd.
ANADA
200-702
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
62.5 mg tablets (50 mg amoxicillin trihydrate, 12.5 mg clavulanic acid); 125 mg tablets (100 mg amoxicillin trihydrate, 25 mg clavulanic acid); 250 mg tablets (200 mg amoxicillin trihydrate, 50 mg clavulanic acid); 375 mg tablets (300 mg amoxicillin trihydrate, 75 mg clavulanic acid)

Dogs

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

Dosage

The recommended dosage is 6.25 mg/lb of body weight twice a day.

Cats

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg twice a day.

Clavamox® Drops

SPL · SPL

Open original
FDA Structured Product Label

Clavamox® Drops

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
55101
Status
RX
Form
Liquid
Route
Oral
Species
Dog, Not Breeding Animals • Cat, Not Breeding Animals
Composition / specifications
When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams of amoxicillin with clavulanate potassium equivalent to 12.5 milligrams of clavulanic acid.

Dogs

Indication

Clavamox Drops are indicated in the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease.

Dosage

The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5–7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Cats

Indication

Clavamox Drops are indicated in the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli. 

Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and susceptibility studies. A culture should be obtained prior to treatment to determine susceptibility of the organisms to Clavamox. Following determination of susceptibility results and clinical response to medication, therapy may be reevaluated.

Dosage

The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5–7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10–14 days or longer. The maximum duration of treatment should not exceed 30 days.

Clavacillin®

SPL · SPL

Open original
FDA Structured Product Label

Clavacillin®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra Veterinary Products LLC
ANADA
200-604
Status
RX
Form
Suspension
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each mL of suspension contains 50 mg of amoxicillin activity as the trihydrate and 12.5 mg of clavulanic acid activity as the potassium salt.

Dogs

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

Dosage

The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Cats

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.

Clavacillin®

SPL · SPL

Open original
FDA Structured Product Label

Clavacillin®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra Veterinary Products LLC
ANADA
200-592
Status
RX
Form
Tablet
Route
Oral
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
62.5 mg (50 mg amoxicillin, 12.5 mg clavulanic acid)
125 mg (100 mg amoxicillin, 25 mg clavulanic acid)
250 mg (200 mg amoxicillin, 50 mg clavulanic acid)
375 mg (300 mg amoxicillin, 75 mg clavulanic acid)

Cats

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg twice a day.Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or for 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs

Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase- producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Amoxicillin trihydrate and clavulanate potassium tablets have been shown to be clinically effective for treating cases of canine periodontal disease.

Dosage

The recommended dosage is 6.25 mg/lb of body weight twice a day.Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Amoxicillin and Clavulanate Potassium Drops SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Amoxicillin and Clavulanate Potassium Drops. Use the source link for the full official labeling record.

Clavacillin SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Clavacillin. Use the source link for the full official labeling record.

Betacilin Clav SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Betacilin Clav. Use the source link for the full official labeling record.

Amoxicillin and Clavulanate Potassium SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Amoxicillin and Clavulanate Potassium. Use the source link for the full official labeling record.

Umbrellin SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Umbrellin. Use the source link for the full official labeling record.

UMBRELLIN SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for UMBRELLIN. Use the source link for the full official labeling record.

Amoxicillin and clavulanate potassium SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Amoxicillin and clavulanate potassium. Use the source link for the full official labeling record.

Amoxicillin and Clavulanate Potassium Drops SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Amoxicillin and Clavulanate Potassium Drops. Use the source link for the full official labeling record.

Betacilin Clav Drops SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Betacilin Clav Drops. Use the source link for the full official labeling record.

Kesium SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Kesium. Use the source link for the full official labeling record.

Clavamox SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Clavamox. Use the source link for the full official labeling record.

Clavamox Drops SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Clavamox Drops. Use the source link for the full official labeling record.

AX Pharmaceutical Corp SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for AX Pharmaceutical Corp. Use the source link for the full official labeling record.

FOI Summary oA 200-709 Approved August 18, 2021.pdf

FOI · FOI

Open original

FOI Summary oA 200-702 Approved April 23, 2021.pdf

FOI · FOI

Open original

N055101_Supp_12_23_1997.pdf

FOI · FOI

Open original

FOI Summary oA 200-604 Approved October 20, 2021.pdf

FOI · FOI

Open original

UCM524262.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed Apr 25, 2026, 10:05 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Amoxicillin and Clavulanate Potassium Amoxicillin and Clavulanate Potassium Drops Amoxicillin and clavulanate potassium Betacilin Clav Betacilin Clav Drops Clavacillin UMBRELLIN Umbrellin
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Liquid, Suspension, Tablet • Oral
Applications: ANADA 200-709 • ANADA 200-702 • NADA 55101 • ANADA 200-604 • ANADA 200-592
NDC: Packages 11695-6991-1 11695-6992-1 11695-6993-1 11695-6994-1 11695-7007-1 17033-451-15 • Products 11695 17033 46066 69043 86136
Documents: 5 (FOI: 5) • SPL: 5 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 0 • Cat 3 • View
Case summaries: 1 (showing 1) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: K05.6
Periodontal disease, unspecified

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Avoid in pets with known penicillin allergy. Use caution with severe kidney disease. (Contraindication, High)
Top reaction signals
Loss of appetite (1) Dullness (1) Drooling (1) Disoriented state (1) Disorientation (1) Discoloured urine (1) Diarrhea (1) Dehydration (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200592 ANADA: 200604 ANADA: 200702 ANADA: 200709 NADA: 55101 NDC Package: 11695-6991-1 NDC Package: 11695-6992-1 NDC Package: 11695-6993-1 NDC Package: 11695-6994-1 NDC Package: 11695-7007-1 NDC Package: 13744-540-01 NDC Package: 13744-541-01 NDC Package: 13744-542-01 NDC Package: 13744-543-01 NDC Package: 17033-451-15 NDC Package: 46066-087-17 NDC Package: 46066-111-60 NDC Package: 46066-112-60 NDC Package: 46066-113-60 NDC Package: 46066-114-60 NDC Package: 54771-1020-1 NDC Package: 54771-1020-2 NDC Package: 54771-1021-1 NDC Package: 54771-1021-2
Package NDC Product NDC Form / Route Status
11695-6991-1 11695 -
11695-6992-1 11695 -
11695-6993-1 11695 -
11695-6994-1 11695 -
11695-7007-1 11695 -
13744-540-01 13744 -
13744-541-01 13744 -
13744-542-01 13744 -
13744-543-01 13744 -
17033-451-15 17033 -
46066-087-17 46066 -
46066-111-60 46066 -
46066-112-60 46066 -
46066-113-60 46066 -
46066-114-60 46066 -
54771-1020-1 54771 -
54771-1020-2 54771 -
54771-1021-1 54771 -
54771-1021-2 54771 -
54771-1022-1 54771 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Amoxicillin and Clavulanate Potassium Drops SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Clavacillin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Betacilin Clav SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Amoxicillin and Clavulanate Potassium SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Umbrellin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • UMBRELLIN SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Amoxicillin and clavulanate potassium SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Amoxicillin and Clavulanate Potassium Drops SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Betacilin Clav Drops SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Kesium SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Clavamox SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Clavamox Drops SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • AX Pharmaceutical Corp SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • FOI Summary oA 200-709 Approved August 18, 2021.pdf • FOI summary • Official • April 10, 2024
    FDA FOI summary for application 200709
  • FOI Summary oA 200-702 Approved April 23, 2021.pdf • FOI summary • Official • Dec. 12, 2023
    FDA FOI summary for application 200702
  • N055101_Supp_12_23_1997.pdf • FOI summary • Official • Jan. 12, 2023
    FDA FOI summary for application 55101
  • FOI Summary oA 200-604 Approved October 20, 2021.pdf • FOI summary • Official • July 25, 2022
    FDA FOI summary for application 200604
  • UCM524262.pdf • FOI summary • Official • March 29, 2022
    FDA FOI summary for application 200592

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 67 Clinical 26 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Avoid in pets with known penicillin allergy. Use caution with severe kidney disease. (Clinical, 2026-04-17)
  • contraindications: Avoid in pets with known penicillin allergy. Use caution with severe kidney disease. (Clinical, 2026-04-15)
  • contraindications: Avoid in pets with known penicillin allergy. Use caution with severe kidney disease. (Clinical, 2026-04-11)
  • contraindications: Avoid in pets with known penicillin allergy. Use caution with severe kidney disease. (Clinical, 2026-02-12)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-21)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-20)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-19)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-17)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
  • overdose_info: Mild overdose may cause more pronounced GI symptoms; extreme overdose could lead to kidney damage or neurologic effects. Supportive care is recommended. (Clinical, 2026-04-25)
  • overdose_info: Mild overdose may cause more pronounced GI symptoms; extreme overdose could lead to kidney damage or neurologic effects. Supportive care is recommended. (Clinical, 2026-04-17)
  • overdose_info: Mild overdose may cause more pronounced GI symptoms; extreme overdose could lead to kidney damage or neurologic effects. Supportive care is recommended. (Clinical, 2026-04-15)
  • overdose_info: Mild overdose may cause more pronounced GI symptoms; extreme overdose could lead to kidney damage or neurologic effects. Supportive care is recommended. (Clinical, 2026-04-11)
  • overdose_info: Mild overdose may cause more pronounced GI symptoms; extreme overdose could lead to kidney damage or neurologic effects. Supportive care is recommended. (Clinical, 2026-02-12)
  • side_effects: GI upset (vomiting/diarrhea), decreased appetite. Rare: allergic reaction. (Clinical, 2026-04-11)
  • storage_handling: Store at room temperature; follow label directions for liquid suspensions. (Clinical, 2026-04-25)
  • storage_handling: Store at room temperature; follow label directions for liquid suspensions. (Clinical, 2026-04-17)
  • storage_handling: Store at room temperature; follow label directions for liquid suspensions. (Clinical, 2026-04-15)
Recent Revisions
  • side_effects updated 2026-04-25 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-25 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-25 10:05 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-21 10:06 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-21 10:06 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-21 10:06 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-21 10:06 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-21 10:06 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-21 10:06 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-20 10:07 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-20 10:07 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-20 10:07 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-20 10:07 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-20 10:07 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-20 10:07 by curated_loader • Official FDA application reference for Senvelgo.
  • monitoring updated 2026-04-19 10:07 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-19 10:07 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-19 10:07 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-19 10:07 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-19 10:07 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Amoxicillin and Clavulanate Potassium for Oral Suspension
RX
Amoxicillin Trihydrate Clavulanate Potassium
Suspension • Oral
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. ANADA 200-709 Approved Apr 10, 2024
Amoxicillin and Clavulanate Potassium Tablets
RX
Amoxicillin Trihydrate Clavulanate Potassium
Tablet • Oral
Label highlights
Official documents
Cronus Pharma Specialities India Private Ltd. ANADA 200-702 Approved Dec 12, 2023
Clavamox® Drops
RX
Amoxicillin Trihydrate Clavulanate Potassium
Liquid • Oral
Label highlights
Official documents
Zoetis Inc. NADA 55101 Approved Jan 12, 2023
Clavacillin®
RX
Amoxicillin Trihydrate Clavulanate Potassium
Suspension • Oral
Label highlights
Official documents
Dechra Veterinary Products LLC ANADA 200-604 Approved Jul 25, 2022
Clavacillin®
RX
Amoxicillin Trihydrate Clavulanate Potassium
Tablet • Oral
Label highlights
Official documents
Dechra Veterinary Products LLC ANADA 200-592 Approved Mar 29, 2022

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
When reconstituted each mL contains 50 mg of amoxicillin as the trihydrate and 12.5 mg of clavulanic acid as the potassium salt.
Dogs
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

Dosage

The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Limitations
Cats
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
62.5 mg tablets (50 mg amoxicillin trihydrate, 12.5 mg clavulanic acid); 125 mg tablets (100 mg amoxicillin trihydrate, 25 mg clavulanic acid); 250 mg tablets (200 mg amoxicillin trihydrate, 50 mg clavulanic acid); 375 mg tablets (300 mg amoxicillin trihydrate, 75 mg clavulanic acid)
Dogs
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

Dosage

The recommended dosage is 6.25 mg/lb of body weight twice a day.

Limitations
Cats
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg twice a day.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Not Breeding Animals • Cat, Not Breeding Animals
Composition / specifications
When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams of amoxicillin with clavulanate potassium equivalent to 12.5 milligrams of clavulanic acid.
Dogs
Indication

Clavamox Drops are indicated in the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease.

Dosage

The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5–7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Limitations
Cats
Indication

Clavamox Drops are indicated in the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli. 

Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and susceptibility studies. A culture should be obtained prior to treatment to determine susceptibility of the organisms to Clavamox. Following determination of susceptibility results and clinical response to medication, therapy may be reevaluated.

Dosage

The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5–7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10–14 days or longer. The maximum duration of treatment should not exceed 30 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each mL of suspension contains 50 mg of amoxicillin activity as the trihydrate and 12.5 mg of clavulanic acid activity as the potassium salt.
Dogs
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

Dosage

The recommended dosage is 6.25 mg/lb (1 mL/10 lb) of body weight twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Limitations
Cats
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg (1 mL) twice a day. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
62.5 mg (50 mg amoxicillin, 12.5 mg clavulanic acid)
125 mg (100 mg amoxicillin, 25 mg clavulanic acid)
250 mg (200 mg amoxicillin, 50 mg clavulanic acid)
375 mg (300 mg amoxicillin, 75 mg clavulanic acid)
Cats
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Dosage

The recommended dosage is 62.5 mg twice a day.Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or for 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs
Indication

For the treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: ß-lactamase-producing Staphylococcus aureus, non-ß-lactamase- producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Amoxicillin trihydrate and clavulanate potassium tablets have been shown to be clinically effective for treating cases of canine periodontal disease.

Dosage

The recommended dosage is 6.25 mg/lb of body weight twice a day.Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

Antibiotic combination used for susceptible bacterial infections (often skin, soft tissue, dental, urinary).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Avoid in pets with known penicillin allergy. Use caution with severe kidney disease.

Side Effects

GI upset (vomiting/diarrhea), decreased appetite. Rare: allergic reaction.

Source: FDA openFDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog Drooling (1) • Dog Diarrhea (1) • Cat Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Neurologic
Circling - neurological disorder (1) • Dog

Showing top 5 for Neurologic.

Behavior
Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Dullness (1) • Dog Disoriented state (1) • Dog Disorientation (1) • Dog Discoloured urine (1) • Dog Dehydration (1) • Cat
Show more (21)
Decreased activity (1) • Dog Death by euthanasia (1) • Dog Death (1) • Cat Cyanotic mucous membranes (1) • Dog Cough (1) • Dog Collapse NOS (1) • Dog Cardiac disorder NOS (1) • Dog Blood in urine (1) • Dog Basophilia (1) • Dog Barking (1) • Dog Aspiration pneumonia (1) • Dog Anaphylaxis (1) • Dog Anal and rectal disorder NOS (1) • Dog Anaemia NOS (1) • Dog Agitation (1) • Dog Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Dog Abnormal radiograph finding (1) • Dog Abnormal pupil light reflex (1) • Dog Abnormal posture NOS (1) • Dog Abnormal cytology (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Domestic Longhair, Male, 11 year • Drug: MSK, Suspension • Reactions: Eye irritation, Eye redness, Accidental exposure • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-075506
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 11.00 Year
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Form: Suspension
Reactions Reported:
Eye irritation Eye redness Accidental exposure
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

Mild overdose may cause more pronounced GI symptoms; extreme overdose could lead to kidney damage or neurologic effects. Supportive care is recommended.

Storage & Handling

Store at room temperature; follow label directions for liquid suspensions.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.